Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences ADME and Predictive Toxicology

Matthias Schwab's Biography

Matthias Schwab, Senior Registrar, Institute of Clinical Pharmacology

Matthias Schwab, Full-Professor of Clinical Pharmacology at the University Tuebingen, Germany, studied medicine at the University Erlangen-Nuernberg, Germany followed by fellowships at the Children's Hospital Nuernberg and the Univ. Hospital Erlangen. A fellowship in Clinical Pharmacology at the Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP), Stuttgart, Germany followed. He received board certifications in Children's Medicine and Clinical Pharmacology. He has held positions at IKP Stuttgart and as visiting professor at St Jude Children’s Research Hospital, Memphis, US before he took over the Chair position of Clinical Pharmacology at the University Tuebingen. He is director of the Dept. Clinical Pharmacology, Univ. Tuebingen and the IKP, Robert Bosch Hospital, Stuttgart. MS received offers as full professor for Clinical Pharmacology at the University Innsbruck (Austria) and the Karolinska Institute (Sweden). He participates in and/or coordinates a number of national/international research networks and committees (e.g., FP7 ITN, Member of the Executive Committee of EACPT, president of the German Society of Clinical Pharmacology, received numerous awards, and is Editor of Pharmacogenetics & Genomics and Section Editor of Genome Medicine). His scientific accomplishments include more than 250 peer reviewed publications. His scientific interests focus on pharmacogenomics of ADME genes with particularly interest in cancer therapy and the application of novel methodologies (e.g. epigenetics, metabonomics).

Matthias Schwab Image

ADME Pharmacogenomics and Cancer: Clinical Consequences and Future Perspectives

Friday, 12 April 2013 at 15:45

Add to Calendar ▼2013-04-12 15:45:002013-04-12 16:45:00Europe/LondonADME Pharmacogenomics and Cancer: Clinical Consequences and Future PerspectivesADME and Predictive Toxicology in Barcelona, SpainBarcelona,

ADME pharmacogenomics (PGx) is a core element in personalized medicine in oncology. Its basic concept is that variability in drug response is a consequence of multiple factors, including genomics, epigenomics, the environment and the patient’s characteristics. An ADME systems pharmacology approach needs to be considered in the future.

Add to Calendar ▼2013-04-11 00:00:002013-04-12 00:00:00Europe/LondonADME and Predictive ToxicologyADME and Predictive Toxicology in Barcelona, SpainBarcelona,